Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports First Quarter 2022 Financial Results May 05, 2022 Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Apr 25, 2022 Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® Apr 23, 2022 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan Apr 22, 2022 Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) Apr 14, 2022 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Mar 14, 2022 Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma Mar 14, 2022 Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results Feb 28, 2022 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets Feb 17, 2022 Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference Jan 05, 2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »